InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,792.80
(
0.59%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
-0.63%
)
Bitcoin
57,658.37
(
0.54%
)
Post# of 252586
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 18
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: ghmm post# 148046

Friday, 08/31/2012 9:31:32 PM

Friday, August 31, 2012 9:31:32 PM

Post# of 252586
Thank you both for the replies.

LGND (and MRK) have both said the drug would be advancing to phase 2. An R&D day shortly after the reverse split seems like too long ago for that decision to have been made though - that would be before the data discussion at the MRK R&D day in January 2012:
http://www.biotechduediligence.com/1/post/2012/01/merck-mrk-rd-day-info-re-bace-alzheimers-disease-program.html

masterlongevity - Do you have access to the abstract or poster from this summer's presentation by MRK? Last I checked with the company, LGND did not have it available and the abstracts didn't seem to be online.

Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up